CN Patent

CN1946417A — 2型血管内皮生长因子受体的抑制剂

Assigned to A Deneckere Hughes Bms Research And Development Co · Expires 2007-04-11 · 19y expired

What this patent protects

本发明涉及新的血管内皮生长因子受体(VEGFR)－结合多肽和使用这些多肽抑制血管内皮生长因子(VEGF)介导的生物活性的方法。本发明还提供了与单结构域结合多肽有关的各种改进。

USPTO Abstract

本发明涉及新的血管内皮生长因子受体(VEGFR)－结合多肽和使用这些多肽抑制血管内皮生长因子(VEGF)介导的生物活性的方法。本发明还提供了与单结构域结合多肽有关的各种改进。

Drugs covered by this patent

Patent Metadata

Patent number
CN1946417A
Jurisdiction
CN
Classification
—
Expires
2007-04-11
Drug substance claim
No
Drug product claim
No
Assignee
A Deneckere Hughes Bms Research And Development Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.